BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21633089)

  • 1. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy.
    Montes-Moreno S; Martinez N; Sanchez-Espiridión B; Díaz Uriarte R; Rodriguez ME; Saez A; Montalbán C; Gomez G; Pisano DG; García JF; Conde E; Gonzalez-Barca E; Lopez A; Mollejo M; Grande C; Martinez MA; Dunphy C; Hsi ED; Rocque GB; Chang J; Go RS; Visco C; Xu-Monette Z; Young KH; Piris MA
    Blood; 2011 Jul; 118(4):1034-40. PubMed ID: 21633089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for qRT-PCR analysis from formalin fixed paraffin embedded tissue sections from diffuse large b-cell lymphoma: Validation of the six-gene predictor score.
    Tekin N; Omidvar N; Morris TP; Conget P; Bruna F; Timar B; Gagyi E; Basak R; Naik O; Auewarakul C; Sritana N; Levy D; Cerci JJ; Bydlowski SP; Pereira J; Dimamay MP; Natividad F; Chung JK; Belder N; Kuzu I; Paez D; Dondi M; Carr R; Ozdag H; Padua RA
    Oncotarget; 2016 Dec; 7(50):83319-83329. PubMed ID: 27825111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients.
    Hu M; Wang X; Liu N; Ding K; Zhang G; Liu X
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34109978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-23a expression in paraffin-embedded specimen correlates with overall survival of diffuse large B-cell lymphoma.
    Wang WL; Yang C; Han XL; Wang R; Huang Y; Zi YM; Li JD
    Med Oncol; 2014 Apr; 31(4):919. PubMed ID: 24659264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
    Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
    BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.
    Cottereau AS; Lanic H; Mareschal S; Meignan M; Vera P; Tilly H; Jardin F; Becker S
    Clin Cancer Res; 2016 Aug; 22(15):3801-9. PubMed ID: 26936916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Green TM; Jensen AK; Holst R; Falgreen S; Bøgsted M; de Stricker K; Plesner T; Mourits-Andersen T; Frederiksen M; Johnsen HE; Pedersen LM; Møller MB
    Br J Haematol; 2016 Sep; 174(6):876-86. PubMed ID: 27196819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wong KK; Ch'ng ES; Loo SK; Husin A; Muruzabal MA; Møller MB; Pedersen LM; Pomposo MP; Gaafar A; Banham AH; Green TM; Lawrie CH
    Exp Mol Pathol; 2015 Dec; 99(3):537-45. PubMed ID: 26341140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
    Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
    World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
    Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
    J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Meng B; Zhang H
    Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
    Prochazka KT; Melchardt T; Posch F; Schlick K; Deutsch A; Beham-Schmid C; Weiss L; Gary T; Neureiter D; Klieser E; Greil R; Neumeister P; Egle A; Pichler M
    Br J Cancer; 2016 Nov; 115(10):1264-1272. PubMed ID: 27764838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.
    Okina S; Yanagisawa N; Yokoyama M; Sakurai Y; Numata Y; Umezawa A; Higashihara M; Murakumo Y
    Int J Hematol; 2015 Dec; 102(6):662-9. PubMed ID: 26449786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients.
    Lim EL; Trinh DL; Scott DW; Chu A; Krzywinski M; Zhao Y; Robertson AG; Mungall AJ; Schein J; Boyle M; Mottok A; Ennishi D; Johnson NA; Steidl C; Connors JM; Morin RD; Gascoyne RD; Marra MA
    Genome Biol; 2015 Jan; 16(1):18. PubMed ID: 25723320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of microRNA-223 and its clinicopathologic correlation in diffuse large B-cell lymphoma].
    Yao XX; Wang JF; Wang YH; Gao N
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):366-70. PubMed ID: 22932402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
    Yang JM; Jang JY; Jeon YK; Paik JH
    J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-21 expression predicts prognosis in diffuse large B-cell lymphoma.
    Li J; Fu R; Yang L; Tu W
    Int J Clin Exp Pathol; 2015; 8(11):15019-24. PubMed ID: 26823838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.